Prospective head-to-head comparison of non-invasive scores for diagnosis of fibrotic MASH in patients with type 2 diabetes
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND Non-invasive scores have been proposed to identify patients with fibrotic, metabolic dysfunction associated steatohepatitis (MASH), who are at the highest risk of progression to complications of cirrhosis and may benefit from pharmacologic treatments. However, data in type 2 diabetes (T2DM) patients are lacking. The aim of this multicenter prospective study was to compare head-to-head FAST (FibroScan-aspartate aminotransferase [AST]), MAST (magnetic resonance imaging [MRI]-AST), MEFIB (magnetic resonance elastography [MRE] plus FIB-4), and FNI (fibrotic NASH index) for detecting fibrotic MASH in T2DM patients. METHODS 330 T2DM outpatients with biopsy-proven metabolic dysfunction associated steatotic liver disease (MASLD) from the QUID-NASH study (NCT03634098), who underwent FibroScan, MRI-PDFF and MRE at the time of liver biopsy (LB) were studied. The main outcome was fibrotic MASH, defined as NAS ≥ 4 (with at least one point each) and fibrosis stage ≥ 2 (centrally reviewed). RESULTS 245 patients (median age 59 years, male 65%, BMI 31 kg/m2; fibrotic MASH 39%) had all data available for scores comparison. FAST and MAST had similar accuracy (AUROCs 0.81 vs. 0.79, p = 0.41) but outperformed FNI (0.74; p = 0.01) and MEFIB (0.68; p < 0.0001). When using original cutoffs, MAST outperformed FAST, MEFIB and FNI when comparing the percentage of correctly classified patients, in whom LB would be avoided (69% vs. 48%, 46%, 39%, respectively; p < 0.001). When using cutoffs specific to our population, FAST outperformed FNI and MAST (56% vs. 40%, and 38%, respectively; p < 0.001). CONCLUSION Our findings show that FAST, MAST, MEFIB and FNI are accurate non-invasive tools to identify T2DM patients with fibrotic MASH in secondary/tertiary diabetes clinics. Cutoffs adapted to T2DM population should be considered. TRIAL REGISTRATION NUMBER NCT03634098.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sterling, R. K., Lissen, E., Clumeck, N., Sola, R., Correa, M. C., Montaner, J., S. Sulkowski, M., Torriani, F. J., Dieterich, D. T., Thomas, D. L., et al. (2006) · Hepatology · doi:10.1002/hep.21178 · Cited by 5,021
Younossi, Z. M., Golabi, P., Paik, J. M., Henry, A., Van Dongen, C., & Henry, L. (2023) · Hepatology · doi:10.1097/hep.0000000000000004 · Cited by 3,383
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.06.003 · Cited by 3,100
Baveno VII – Renewing consensus in portal hypertension
de Franchis, R., Bosch, J., Garcia-Tsao, G., Reiberger, T., Ripoll, C., Abraldes, J. G., Albillos, A., Baiges, A., Bajaj, J., Bañares, R., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.12.022 · Cited by 2,930
Self-citationRinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667
Calibration: the Achilles heel of predictive analytics
On behalf of Topic Group ‘Evaluating diagnostic tests and prediction models’ of the STRATOS initiative, Van Calster, B., McLernon, D. J., van Smeden, M., Wynants, L., & Steyerberg, E. W. (2019) · BMC Medicine · doi:10.1186/s12916-019-1466-7 · Cited by 2,650
Younossi, Z. M., Golabi, P., de Avila, L., Paik, J. M., Srishord, M., Fukui, N., Qiu, Y., Burns, L., Afendy, A., & Nader, F. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.06.021 · Cited by 2,235
A Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039
Berzigotti, A., Tsochatzis, E., Boursier, J., Castera, L., Cazzagon, N., Friedrich-Rust, M., Petta, S., & Thiele, M. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.05.025 · Cited by 1,925
Singh, S., Allen, A. M., Wang, Z., Prokop, L. J., Murad, M. H., & Loomba, R. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.04.014 · Cited by 1,748
Cited by
Tacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), & European Association for the Study of Obesity (EASO) (2024) · Obesity Facts · doi:10.1159/000539371 · Cited by 471
Metabolic dysfunction-associated steatotic liver disease in adults
Huang, D. Q., Wong, V. W. S., Rinella, M. E., Boursier, J., Lazarus, J. V., Yki-Järvinen, H., & Loomba, R. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00599-1 · Cited by 293
Fan, W., Bradford, T. M., & Török, N. J. (2024) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.15184 · Cited by 25
Loomba, R., Daniel, P. C.-Y. N., Amangurbanova, M., Bettencourt, R., Madamba, E., Siddiqi, H., Richards, L., Gottwald, M. D., Feng, S., Margalit, M., et al. (2026) · Hepatology · doi:10.1097/hep.0000000000001396 · Cited by 17
Metadata
- Authors
- Castera, L., Garteiser, P., Laouenan, C., Vidal-Trécan, T., Vallet-Pichard, A., Manchon, P., Paradis, V., Czernichow, S., Roulot, D., Larger, E., Pol, S., Bedossa, P., Correas, J.-M., Valla, D., Gautier, J.-F., Van Beers, B. E., Bellili, D., Bessadi, O., Da Silveira, C., Djelouat, F. Z., Girard, B., Legrand, V., Neveux, N., Meziani, M., Roy, L., Sekour, D., Sens, M., Slimani, M., Zatout, O., Bachelet, D., Bhavsar, K., Mullaert, B. B.-B. J., Marcault, E., Si-Mohammed, N., Cosson, E., Albuquerque, M., Doblas, S., Hammoutene, A., Gonzalez Montpetit, E., Pagé, G., Parfait, B., Postic, C., Lehuen, A., Toubal, A., Rousseau, C., Fruchet, B., Soulard, P., Gouda, Z., Vidaud, M., Letourneur, F., Renault, G., Scharfmann, R., Ait-Boudaoud, A., Barsamian, C., Carette, C., Rives-Lange, C., Baida, R., Couture, O., Decombas, S., Deffieux, T., Nguyen, T.-M., Tanter, M., Baltauss, T., Balzac, E.-L., Barbier Saint Hilaire, P., Delerive, P., Duvivier, V., Fillon, A., Geronimi, J., Laplume, J., Werner, E., Xuereb, L., Liechti, R., Martin, O., Mehl, F., Pruess, M., Castille, J.-M., Drane, F., Deckmyn, O., Castelli, F., Cousin, B. C. E., Fenaille, F., Guilbaud, L., Lohier, A., Chambellin, F., Laaland, L., Clusel, C., Hauduroy, M., & Pautre, P.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2024-08
- Volume
- 81
- Issue
- 2
- Pages
- 195-206
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W4393230605
- Cited by
- 53
- References
- 20
- FWCI
- 13.86
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prospective head-to-head comparison of non-invasive scores for diagnosis of fibrotic MASH in patients with type 2 diabetes. https://app.cochat.ai/papers/10.1016/j.jhep.2024.03.023
- The paper
- Castera, L., Garteiser, P., Laouenan, C., Vidal-Trécan, T., Vallet-Pichard, A., Manchon, P., Paradis, V., Czernichow, S., Roulot, D., Larger, E., Pol, S., Bedossa, P., Correas, J.-M., Valla, D., Gautier, J.-F., Van Beers, B. E., Bellili, D., Bessadi, O., Da Silveira, C., . . . Pautre, P. (2024). Prospective head-to-head comparison of non-invasive scores for diagnosis of fibrotic MASH in patients with type 2 diabetes. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2024.03.023
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.